IMMray platform Proprietary blood-based biomarker platform - PowerPoint PPT Presentation

IMMray ™ platform Proprietary blood-based biomarker platform Significant unmet medical need for early Initial addressable market in EU/US: USD 4.4bn Familial, new onset diabetes type II, early symptoms detection of pancreatic cancer Near-term commercial opportunity Expected sales starting in Q3 2020 IMMray ™ PanCan-d Prospective PDAC clinical studies Interim analysis end of 2020 paving the way for reimbursement Aiming for >10,000 subjects in three major risk groups Additional upside opportunity Lung cancer collaboration with a pharma company leveraging IMMray ™ platform Rheumatoid arthritis ongoing discovery tool study

MICHAEL PETTIGREW MATS GRAHN ROLF EHRNSTRÖM SVP Sales NA CEO, MSc CSO, MSc • VP Sales Americas Thermo • CVP Marketing at Dako. • CSO & CVP R&D Dako. Fisher Scientific • VP Marketing at, GE • CSO Gyros, Amersham, • VP Corp Development Healthcare, Amersham, Pharmacia Biotech Magellan Pharmacia Biotech • +30 years in industry • VP sales GE Healthcare • + 30 years in industry • +30 years in industry HANS LILJENBORG LAURA CHIRICA CFO CCO, Ph. D • VP Sales & Mktg • CFO Jolife Euro Diagnostica AB • CFO Vivoline • Marketing Sartorious • Owner Adays AB • Marketing Dako • Marketing GE Healthcare • +20 years in industry LOTTA BLOMGREN HANS CHRISTIAN PEDERSEN PETER SCHULZ KNAPPE Operations Director VP Business Development, Ph.D CTO, MD, Ph.D • VP Tech. Ops Euro Diagnostica • Director Business Development, • CSO Protagen. AG, Germany AB Companion diagnostics and • CSO Proteome Sciences Ltd, • Head of Supply Chain Bioglan AB Pharma Services, Unilabs United Kingdom • Director Tech. Support Ferring A/S • ,Head of Companion • Head of Process Dev. Ferring AB • +30 years in industry Diagnostics and IHC reagents, • Process Dev. and Project Global Marketing Agilent/Dako Management at Astra / Pharmacia The Management team is supported by an experienced Board of Directors

IMMray TM Technology

Indication Discovery / early dev. Optimization Commercial Test Model Verification & Validation Commercial Pancreatic cancer Lung cancer Rheumatoid arthritis

IMMray TM ctDNA

Five Year Survival ~50% <5%

• • • • • • • • •

IMMray TM PanCan-d IMMray TM PanCan-d IMMray PanCan-d Verification study Validation study commercial test discovery and optimization study model study development studies • • • • • Test the Locked signature Locked signature Defined candidate Optimize Launch and algorithms candidate’s and algorithms signature and candidate’s • • Known samples Blinded samples commercial algorithm commercial signature signature and • Fine tune algorithm algorithm • Full IMMray TM array



• • • • • • • • • • • • • • • • • •

• • • • IMMray TM PanCan-d IMMray TM PanCan-d IMMray PanCan-d Verification study Validation study Launch commercial test discovery and optimization study model study development studies • • • • Locked signature • Test the Locked signature Defined candidate Optimize and algorithms and algorithms candidate’s signature and candidate’s • • commercial Known samples Blinded samples commercial algorithm signature signature and • Fine tune algorithm algorithm • Full IMMray TM array

• • • • • •

1 • 2 • • 3 • • • 4

Test document Test ordered Test initiated Blood collected Sample Shipped Tested/Reported

 • • • • • • • • • • • • *

IMMray ™ RA -d target clinical use Early RA - PRIMARY CARE Developing RA Established RA - REUMATOLOGITS Patients with pain and clear clinical symptoms EULAR recommendation for early RA Referral to specialist ACR criteria and scoring CCP test: specificity 96%; sensitivity 72% ~80% CCP negative ~50% CCP negative ~25-30% CCP negative Next steps - RA RA discovery RA discovery RA signature test Verification study Validation study studies studies study • • Locked signature and Locked signature and • • • RA vs controls with Double negative vs Test the candidate algorithms algorithms other diseases healthy signature • • Known samples Blinded samples • • having RA like All RA vs healthy Fine tune algorithm symptoms • Define candidate commercial signature and algorithm

Lung cancer and RA are here

• • • • • •